Inhaled therapy aims to cut lung Tumors' sugar supply

NCT ID NCT07631299

Not yet recruiting Disease control Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests whether an inhaled drug called AER101 can reduce glycolysis—the process cancer cells use to break down sugar for energy—in early-stage non-small cell lung cancer. Participants inhale the drug three times daily for two weeks before their scheduled surgery. The goal is to see if the drug can shrink or weaken the tumor by cutting its fuel supply.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AER101
What this could lead to: If it works, this could point toward a new way to treat early-stage lung cancer by starving tumor cells of energy before surgery.
What could go wrong: This is a very small early-phase study with only 5 participants, so results may not apply widely. The drug may not reduce glycolysis enough to affect the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER STAGE I are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-SMALL CELL LUNG CANCER STAGE I NON-SMALL CELL LUNG CANCER STAGE II

Contacts and locations

Locations

OU Medical Center Hospital

Oklahoma City, Oklahoma, 73106, United States
Stephenson Cancer Center

Oklahoma City, Oklahoma, 73106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.